¼¼°èÀÇ ½ÃÄö½Ì ½Ã¾à ½ÃÀå
Sequencing Reagents
»óǰÄÚµå : 1533956
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,209,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,629,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½ÃÄö½Ì ½Ã¾à ½ÃÀåÀº 2030³â±îÁö 128¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2023³â¿¡ 63¾ï ´Þ·¯·Î ÃßÁ¤µÈ ½ÃÄö½Ì ½Ã¾à ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 10.8%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç 2030³â¿¡´Â 128¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Â÷¼¼´ë ½ÃÄö½Ì ±â¼úÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 11.3%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 84¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 3¼¼´ë ½ÃÄö½Ì ±â¼ú ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 10.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 17¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 14.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ ½ÃÄö½Ì ½Ã¾à ½ÃÀåÀº 2023³â 17¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°èÀÇ 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 28¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾ÈÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 14.7%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº °¢°¢ 8.0%¿Í 9.3%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 8.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ½ÃÄö½Ì ½Ã¾à ½ÃÀå : ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ ¿ä¾à

½ÃÄö½Ì ½Ã¾àÀº À¯ÀüüÇÐ ¹× ºÐÀÚ »ý¹°ÇÐ ºÐ¾ß¿¡¼­ DNA ¹× RNA ¼­¿­ÀÇ Á¤È®Çϰí È¿À²ÀûÀÎ ÇØµ¶À» °¡´ÉÇÏ°Ô ÇÏ´Â Áß¿äÇÑ ±¸¼º¿ä¼ÒÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¾àÀº È¿¼Ò, ´ºÅ¬·¹¿ÀƼµå, ÇÁ¶óÀ̸Ó, ¿ÏÃæ¾× µîÀÇ ´Ù¾çÇÑ ¹°ÁúÀ» Æ÷ÇÔÇϸç, °¢°¢Àº ½ÃÄö½Ì °úÁ¤¿¡¼­ ƯÁ¤ÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, DNA ÁßÇÕÈ¿¼Ò¿Í °°Àº È¿¼Ò´Â »õ·Î¿î DNA °¡´ÚÀÇ ÇÕ¼ºÀ» ÃËÁøÇϰí, ´ºÅ¬·¹¿ÀƼµå´Â ÀÌµé °¡´Ú¿¡ ÅëÇյǴ ºôµù ºí·ÏÀÔ´Ï´Ù. ÇÁ¶óÀ̸Ӵ DNA ÇÕ¼ºÀÇ Ãâ¹ßÁ¡ÀÌ µÇ°í, ¿ÏÃæ¾×Àº È¿¼Ò ¹ÝÀÀ¿¡ ÇÊ¿äÇÑ ÃÖÀûÀÇ pH¿Í À̿ Á¶°ÇÀ» À¯ÁöÇÕ´Ï´Ù. °¡Àå »¡¸® °³¹ßµÈ ¹æ¹ý Áß ÇϳªÀÎ Sanger Sequence´Â µðµ¥¿Á½Ã´ºÅ¬·¹¿ÀƼµå Æ®¸®Æ÷½ºÆäÀÌÆ®(ddNTPs)¸¦ »ç¿ëÇÏ¿© DNA °¡´ÚÀÇ ¿¬ÀåÀ» ƯÁ¤ ¿°±â¿¡¼­ Á¤Áö½ÃÄÑ DNA ¼­¿­ÀÇ °áÁ¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì(NGS) ±â¼úÀº ¸¹Àº ÀÀ¿ë ºÐ¾ß¿¡¼­ Sanger ½ÃÄö½ÌÀ» ´ëüÇϰí Ç¥Áö µÈ ´ºÅ¬·¹¿ÀŸÀ̵å¿Í Æú¸®¸Ó ¶óÁ¦ÀÇ Á¶ÇÕÀ» Ȱ¿ëÇÏ¿© ¾öû³­ ¾çÀÇ ½ÃÄö½Ì µ¥ÀÌÅ͸¦ ½Å¼ÓÇϰí Àú·ÅÇÑ ºñ¿ëÀ¸·Î »ý¼ºÇÕ´Ï´Ù. ½ÃÄö½ÌÀÇ Á¤È®µµ, °¨µµ ¹× È¿À²Àº ÀÌ·¯ÇÑ ½Ã¾àÀÇ Ç°Áú°ú Á¶¼º¿¡ Å©°Ô ÀÇÁ¸Çϱ⠶§¹®¿¡ ±âÃÊ ¿¬±¸¿¡¼­ Áø´Ü, ÀÓ»ó¿¡ À̸£±â±îÁö ±¤¹üÀ§ÇÑ ÀÀ¿ë ºÐ¾ß¿¡¼­ ÇʼöÀûÀÔ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ½ÃÄö½Ì ½Ã¾àÀÇ °³¹ß°ú »ç¿ë¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¿¡·¯À²À» Àú°¨ÇÏ´Â °íÃæ½Çµµ Æú¸®¸Ó¶óÁ¦³ª, ½ÅÈ£ °ËÃâÀ» °­È­ÇÏ´Â °³·®Çü Çü±¤ »ö¼Ò µîÀÇ ±â¼ú Çõ½Å¿¡ ÀÇÇØ ½ÃÄö½Ì ±â¼úÀÇ Á¤¹Ðµµ¿Í 󸮷®ÀÌ ´ëÆø Çâ»óµÇ¾ú½À´Ï´Ù. ¿©·¯ ½Ã·á¸¦ µ¿½Ã¿¡ ó¸®ÇÒ ¼ö ÀÖ´Â °í󸮷® ½ÃÄö½Ì Ç÷§ÆûÀº Ç¥ÁØÈ­µÇ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â °íǰÁú ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ³ô¿©ÁÝ´Ï´Ù. ¾÷°è °¢ ȸ»ç´Â ³ôÀº È¿À²¼º, ³·Àº ¿À·ùÀ² ¹× ´Ù¾çÇÑ ½ÃÄö½Ì Ç÷§Æû°úÀÇ ³ôÀº ȣȯ¼ºÀ» Á¦°øÇÏ´Â ½Ã¾à °³¹ß¿¡ Áö¼ÓÀûÀ¸·Î ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ´ÜÀÏ ºÐÀÚ ½Ç½Ã°£(SMRT) ¹× ³ª³ëÆ÷¾î ¼­¿­¿¡ »óÀÀÇÏ´Â ½Ã¾àÀÇ µµÀÔÀº º¹ÀâÇÑ À¯Àüü ¹× ¿¡ÇÇÀ¯Àüü ¿¬±¸¿¡ »õ·Î¿î °¡´É¼ºÀ» °¡Á®¿Ô½À´Ï´Ù. ¶ÇÇÑ ½ÃÄö½Ì ¿öÅ©Ç÷ο쿡¼­ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)ÀÇ ÅëÇÕÀº ½Ç½Ã°£À¸·Î ½ÃÄö½Ì ÇÁ·Î¼¼½º¿¡ ÀûÀÀÇϰí ÃÖÀûÈ­ÇÒ ¼ö ÀÖ´Â º¸´Ù ½º¸¶Æ®ÇÑ ½Ã¾à °³¹ß¿¡ ±æÀ» ¿­°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸·Î ¿¬±¸ÀÚµéÀº À¯ÀüüÇп¡¼­ °¡´ÉÇÑ ÀÏÀÇ ÇѰ踦 ³ÐÇô »õ·Î¿î ¹ß°ß°ú ÀÀ¿ëÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

½ÃÄö½Ì ½Ã¾à ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù. ù°, °³ÀÎÈ­ ÀÇÇÐ, Áúº´ Áø´Ü ¹× Ä¡·á¿¡¼­ À¯ÀüüÇÐÀÇ ÀÀ¿ë È®´ë°¡ °íǰÁú ½ÃÄö½Ì ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÈ ÀÇ·á´Â ȯÀÚ ÇÑ »ç¶÷ÀÇ Æ¯¼º¿¡ ¸Â´Â Ä¡·á¸¦ ÇÏ´Â °ÍÀ¸·Î, ÃÖÀûÀÇ Ä¡·á Àü·«À» È®ÀÎÇϱâ À§ÇØ À¯Àüü Á¤º¸¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Àΰ£ À¯Àüü ÇÁ·ÎÁ§Æ®¿Í ÃÖ±Ù 100,000¸í À¯Àüü ÇÁ·ÎÁ§Æ®¿Í °°Àº ´ë±Ô¸ð ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÈûÀÔ¾î À¯Àüü ¿¬±¸ÀÇ ±ÞÁõÀº ÀÌ·¯ÇÑ ½Ã¾à¿¡ ´ëÇÑ Å« ¼ö¿ä¸¦ °è¼ÓÇØ¼­ À̲ø°í ÀÖ½À´Ï´Ù. º¸´Ù È¿À²ÀûÀÎ NGS Ç÷§Æû °³¹ß°ú °°Àº ½ÃÄö½Ì ±â¼úÀÇ Áøº¸´Â ½ÃÄö½ÌÀ» ´õ¿í Ä£¼÷ÇÏ°í °æÁ¦ÀûÀ¸·Î ¸¸µé¾î ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. À¯Àü¼º Áúȯ°ú ¾ÏÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÓ»ó ÇöÀå¿¡¼­ ½ÃÄö½ÌÀÇ ÀÌ¿ëÀÌ Áõ°¡ÇÏ°í ½ÃÀåÀ» ´õ¿í ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ³ó¾÷ ¹× ȯ°æ ¿¬±¸¿¡¼­ ½ÃÄö¼­ÀÇ ÀÌ¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©ÇÏ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. Á¦¾à ȸ»ç´Â »õ·Î¿î â¾à Ç¥ÀûÀ» ÆÄ¾ÇÇϰí Á¤¹Ð Ä¡·á¸¦ °³¹ßÇϱâ À§ÇØ ½ÃÄö¼­¸¦ »ç¿ëÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀÌ ÁøÈ­¸¦ °è¼ÓÇϰí ÀÖ´Â °¡¿îµ¥, ½ÃÄö½Ì ½Ã¾à ½ÃÀåÀº ±â¼úÀÇ Áøº¸³ª ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ÀÇ ÀÀ¿ë È®´ë¿¡ ÃßÁøµÇ¾î Áö¼ÓÀûÀÎ ¼ºÀå°ú Çõ½ÅÀ» ÀÌ·ç´Â ż¼°¡ °®Ãß¾îÁö°í ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(Àü 86°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Sequencing Reagents Market to Reach US$12.8 Billion by 2030

The global market for Sequencing Reagents estimated at US$6.3 Billion in the year 2023, is expected to reach US$12.8 Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2023-2030. Next Generation Sequencing Technology, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Third Generation Sequencing Technology segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 14.7% CAGR

The Sequencing Reagents market in the U.S. is estimated at US$1.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Sequencing Reagents Market - Key Trends and Drivers Summarized

Sequencing reagents are crucial components in the field of genomics and molecular biology, enabling the accurate and efficient decoding of DNA and RNA sequences. These reagents include a diverse array of substances such as enzymes, nucleotides, primers, and buffers, each playing a specific role in the sequencing process. For example, enzymes like DNA polymerases facilitate the synthesis of new DNA strands, while nucleotides are the building blocks that get incorporated into these strands. Primers provide the starting point for DNA synthesis, and buffers maintain the optimal pH and ionic conditions necessary for enzymatic reactions. In Sanger sequencing, one of the earliest methods developed, dideoxynucleotide triphosphates (ddNTPs) are used to terminate DNA strand elongation at specific bases, allowing for the determination of the DNA sequence. Next-generation sequencing (NGS) technologies, which have largely supplanted Sanger sequencing for many applications, utilize a combination of labeled nucleotides and polymerases to generate vast amounts of sequence data quickly and at a lower cost. The accuracy, sensitivity, and efficiency of sequencing heavily depend on the quality and composition of these reagents, making them indispensable in a wide range of applications, from basic research to diagnostics and clinical use.

Technological advancements have significantly impacted the development and use of sequencing reagents. Innovations such as high-fidelity polymerases, which have reduced error rates, and improved fluorescent dyes, which enhance signal detection, have greatly increased the accuracy and throughput of sequencing technologies. High-throughput sequencing platforms, which can process multiple samples simultaneously, have further driven the demand for standardized, reliable, and high-quality reagents. Companies in the industry are continuously striving to develop reagents that offer higher efficiency, lower error rates, and greater compatibility with various sequencing platforms. For instance, the introduction of reagents compatible with single-molecule real-time (SMRT) sequencing and nanopore sequencing has opened new possibilities for studying complex genomes and epigenomes. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) in sequencing workflows is paving the way for the development of smarter reagents that can adapt and optimize sequencing processes in real-time. These advancements are enabling researchers to push the boundaries of what is possible in genomics, leading to new discoveries and applications.

The growth in the sequencing reagents market is driven by several factors. Firstly, the expanding applications of genomics in personalized medicine, disease diagnosis, and treatment are propelling the demand for high-quality sequencing reagents. Personalized medicine, which tailors medical treatment to the individual characteristics of each patient, relies heavily on genomic information to identify the best therapeutic strategies. The surge in genomic research, fueled by large-scale initiatives like the Human Genome Project and the more recent 100,000 Genomes Project, continues to generate significant demand for these reagents. Advances in sequencing technologies, such as the development of more efficient NGS platforms, are also driving market growth by making sequencing more accessible and affordable. The increasing prevalence of genetic disorders and cancer has led to a rise in the use of sequencing in clinical settings, further boosting the market. Additionally, the growing use of sequencing in agricultural and environmental research is another factor contributing to market expansion. Pharmaceutical companies are increasingly using sequencing to identify new drug targets and to develop precision therapies. As these trends continue to evolve, the sequencing reagents market is poised for sustained growth and innovation, driven by technological advancements and expanding applications across various fields.

Select Competitors (Total 86 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â